loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations
Open ICICI 3-in-1 Account

Tatva Chintan Pharma Chem Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Tatva Chintan Pharma Chem Ltd. 18 May 2026 17:25 PM
Result PDF

Q4FY26 & FY26 Result Announced for Tatva Chintan Pharma Chem Ltd.

Specialty Chemicals company Tatva Chintan Pharma Chem announced Q4FY26 & FY26 results

Consolidated Financial Highlights:

  • Revenue from Operations: For Q4FY26, revenue stood at Rs 1,341.44 million, representing a YoY increase of 24.36% from Rs 1,078.64 million in Q4FY25 and a QoQ increase of 2.14% from Rs 1,313.34 million in Q3FY26.
  • Total Income: The total income for Q4FY26 was Rs 1,337.96 million, compared to Rs 1,085.86 million in Q4FY25 (up 23.22% YoY) and Rs 1,330.68 million in Q3FY26 (up 0.55% QoQ).
  • Net Profit: The company reported a net profit of Rs 103.21 million in Q4FY26, marking a significant YoY increase of 902.04% from Rs 10.30 million in Q4FY25, but a QoQ decrease of 31.94% from Rs 151.65 million in Q3FY26.
  • Annual Performance (FY26): Revenue from operations for the full year FY26 was Rs 5,058.58 million, up 32.18% from Rs 3,827.14 million in FY25. Net profit for FY26 increased by 636.11% to Rs 420.54 million from Rs 57.13 million in FY25.
  • Earnings Per Share (EPS): Basic and Diluted EPS for Q4FY26 stood at Rs 4.41, compared to Rs 0.44 in Q4FY25 and Rs 6.49 in Q3FY26. For the full year FY26, EPS was Rs 17.98.

Standalone Financial Highlights:

  • Revenue from Operations: Standalone revenue for Q4FY26 was Rs 1,326.65 million, up 23.24% YoY from Rs 1,076.48 million in Q4FY25 and down 4.27% QoQ from Rs 1,385.88 million in Q3FY26.
  • Total Income: Total standalone income for Q4FY26 was Rs 1,322.96 million, compared to Rs 1,089.43 million in Q4FY25 and Rs 1,403.22 million in Q3FY26.
  • Net Profit: Standalone net profit for Q4FY26 was Rs 90.23 million, up 724.02% YoY from Rs 10.95 million in Q4FY25 and down 43.55% QoQ from Rs 159.84 million in Q3FY26.
  • Annual Performance (FY26): Standalone revenue from operations for the full year FY26 reached Rs 4,962.96 million, an increase of 35.45% from Rs 3,664.15 million in FY25. Net profit for FY26 stood at Rs 390.82 million, a massive increase compared to Rs 3.27 million in FY25.

Business Highlights:

  • Segment Performance: The company operates in only one reportable business segment, which is Specialty Chemicals.
  • Dividend: The Board of Directors recommended a final dividend of Rs 2/- (20%) per equity share of face value Rs 10/- each for the financial year 2025-26, subject to shareholder approval.
  • Auditor Appointments: The Board approved the appointment of M/s. Zarna Thakar & Associates as Cost Auditor and RSM Astute Consultech Private Limited as Internal Auditor of the company for the financial year 2026-27.
  • Subsidiaries: The consolidated financial results include the results of two subsidiaries: Tatva Chintan USA Inc. and Tatva Chintan Europe B.V.

Result PDF

Result PDF

Specialty Chemicals company Tatva Chintan Pharma Chem announced Q3FY26 results

  • Revenue: Rs 1,313.34 crore against Rs 858.96 crore during Q3FY25.
  • PBT: Rs 176.58 crore against Rs -2.35 crore during Q3FY25.
  • PAT: Rs 151.65 crore against Rs 1.38 crore during Q3FY25.
  • EPS: Rs 6.49 for Q3FY26.

Result PDF

Specialty Chemicals company Tatva Chintan Pharma Chem announced Q2FY26 results

  • Revenue from Operations: Rs 1,235 million compared to Rs 835 million during Q2FY25, change 48%.
  • EBIDTA: Rs 222 million compared to Rs 56 million during Q2FY25, change 298%.
  • EBIDTA Margin: 18.0% for Q2FY26.
  • PAT: Rs 99 million compared to Rs -7 million during Q2FY25.
  • PAT Margin: 8.0% for Q2FY26.

Result PDF

Specialty Chemicals company Tatva Chintan Pharma Chem announced Q1FY26 results

  • Revenue from Operations: Rs 1,169 million compared to Rs 1,055 million during Q1FY25, change 11%.
  • EBIDTA: Rs 173 million compared to Rs 126 million during Q1FY25, change 37%.
  • EBIDTA Margin: 14.8% for Q1FY26.
  • PAT: Rs 67 million compared to Rs 52 million during Q1FY25, change 28%.
  • PAT Margin: 5.7% for Q1FY26.
  • EPS: Rs 2.84 for Q1FY26.

Result PDF

Specialty Chemicals company Tatva Chintan Pharma Chem announced Q3FY25 results

  • Revenue from Operations: Rs 859 million in Q3FY25 ( 2% YoY).
  • Total Income: Rs 859 million in Q3FY25 ( 1% YoY).
  • EBITDA (Excl. Other Income): Rs 71 million in Q3FY25 (-36% YoY).
  • EBITDA Margin: 8.2% in Q3FY25 (vs. 13.1% in Q3FY24).
  • Profit Before Tax (PBT): Rs (2) million in Q3FY25 (vs. Rs 52 million in Q3FY24).
  • Profit After Tax (PAT): Rs 1 million in Q3FY25 (-96% YoY).
  • PAT Margin: 0.2% in Q3FY25 (vs. 4.1% in Q3FY24).

Chairman & MD Chintan Shah Commented: "We endeavor to grow organically by incorporating innovative ideas in our operations, product development and increasing our market presence across product categories"

During Q3FY25, the company reported revenue from operations of Rs 859 million, 2% YoY increase. EBITDA during the quarter was at Rs 71 million, 36% YoY decline. EBIDTA margins were at 8.2% v/s 13.1% in Q3FY24.

During 9MFY25, the company reported revenue from operations of Rs 2,749 million, 7% YoY decline. EBITDA during same period was at Rs 256 million, 51% YoY decline. EBIDTA margins were at 9.3% v/s 17.8% in 9MFY25.

As we step into this promising new year 2025, we at TATVA CHINTAN are confident to finally reap the rewards of the hard work, persistence, and resilience that have defined our efforts over the past few quarters. Overall, the market situation continues to remain subdued in terms of demand but we are beginning to see a faint sense of improvement in the market. Industry as a whole seems to have begun the path to recovery. While we may not have completely left the challenges of the past behind, there are encouraging signs pointing toward better business prospects over the coming quarters. Raw material prices have shown relative stability, and sea freight rates have moderated.

We are pleased to inform that we have successfully started distillation plant in January 2025. This new facility will significantly ease production capacities to manufacture some of our major products

Our focus is on development of products for use in semiconductor and electronics industry which will become our growth engine after three years. We have made significant headway in coming close to the ultra-high purity quality requirements.

In these turbulent times, the strength that has kept us resilient and afloat has been our unwavering R&D capabilities. Our vision for the future is deeply embedded in the projects we undertake in R&D, which boasts a robust pipeline of high-value products with immense business potential.

Result PDF

Specialty Chemicals company Tatva Chintan Pharma Chem announced H1FY25 & Q2FY25 results

  • During Q2FY25, the company reported revenue from operations of Rs 835 million, decline by 14% YoY. EBITDA during the quarter was at Rs 56 million, decline by 72% YoY. EBIDTA margins were at 6.7% v/s 20.9% in Q2FY24.
  • During H1FY25, the company reported revenue from operations of Rs 1,890 million, decline by 10% YoY. EBITDA during same period was at Rs 182 million, decline by 56% YoY. EBIDTA margins were at 9.6% v/s 19.7% in H1FY24.

Chintan Shah, CMD, Tatva Chintan Pharma Chem, said: "We continue to grow organically by incorporating innovative ideas across operations and increasing our product portfolio across product categories.

The specialty chemical industry continues to face challenges across major end-user sectors. These challenges are arising largely from weaker global demand and increased competition from Chinese suppliers. Owing to geopolitical issues the long transit times is also hurting the industry. Among these challenges we also see some positives like ongoing reduction in freight rates, destocking by the customers is nearly ending and bottoming of key raw material prices. We foresee the trend of weaker demand will continue through Q3 as customers are cautious about the inventory levels towards the end of their financial year. We anticipate gradual uptick in demand from Q4 and global demands will improve over the coming quarters.

We have a robust pipeline of products across various stages like R&D, pilot level, plant scale, and those under approval or recently approved. These products are poised to generate additional revenue beyond the company’s current turnover. Despite the current challenges, I continue to remain genuinely optimistic. We have multiple products under commercialisation which will lead to a strong
growth. At TATVA CHINTAN, we are confident in our ability to navigate these tough times with resilience, while continuing to nurture and strengthen our relationships with existing customers and also bringing in new products and new customers onboard."

Result PDF

Specialty Chemicals company Tatva Chintan Pharma Chem announced Q1FY24 results:

  • Revenue from operations of Rs 1,143.64 million in Q1FY24 compared to Rs 884.02 million in Q1FY23, up 29.37% YoY
  • EBITDA (Excl. other income) of Rs 213.43 million in Q1FY24 compared to Rs 152.17 million in Q1FY23, up 40.26% YoY
  • EBITDA Margin of 18.66% in Q1FY24 compared to 17.21% in Q1FY23 
  • Profit before tax of Rs 134.20 million in Q1FY24 compared to Rs 136.95 million in Q1FY23, down 2.01% YoY
  • Profit after tax of Rs 95.04 million in Q1FY24 compared to Rs 97.97 million in Q1FY23, down 2.99% YoY
  • PAT margin of 8.31% in Q1FY24 compared to 11.08% in Q1FY23 
  • Cash profit of Rs 155.16 million in Q1FY24 compared to Rs 121.3 million in Q1FY23, up 27.91% YoY

Commenting on the results, Chintan Shah, Managing Director said, "I am pleased to inform you that TATVA CHINTAN has begun this financial year on a satisfactory note, in line with our expectations and we expect the improvement to gradually continue over the coming quarters. The year has started with better off-take and a favorable product mix translating into better numbers for this quarter.

During this quarter, the company has reported revenue from operations of Rs 1,144 million, a growth of 29% YoY from Rs 884 million. EBITDA during the quarter was at Rs 213 million, a growth of 40% YoY from Rs 152 million. EBIDTA margins were at 18.7% v/s 17.2% in Q1FY23. The inventory (other than spares and packing materials) at consolidated levels has come down by nearly Rs 125 million from Rs 1,325 million as of March 2023 to Rs 1,200 million as of June 2023. The logistic costs have steadily reduced to realistic levels which has come as a breather. Also, the price reduction in the chemical space seems to have lost pace and the prices have begun to stabilize in the past few weeks.

I am quite happy and proud, to inform you that we successfully commenced commercial production from the newly expanded facility at Dahej SEZ. With this the installed reactor capacity increased to 500KL from 294KL and assembly lines increased from 27 to 39."

 

 

 

Result PDF

Specialty chemicals company Tatva Chintan Pharma Chem announced Q4FY23 & FY23 results:

  • Q4FY23 vs Q4FY22:
    • Revenue from operation: Rs 1,245.11 million vs Rs 985.31 million, up 26.37% YoY
    • EBITDA (Excl. Other Income): Rs 162.74 million vs Rs 219.94 million, down 26.01% YoY
    • EBITDA margin: 13.07% vs 22.32%
    • Profit before tax: Rs 78.02 million vs Rs 189.76 million, down 58.88% YoY
    • Profit after tax: Rs 169.54 million vs Rs 175.09 million, down 3.17% YoY
    • PAT margin: 13.62% vs 17.77%
  • FY23 vs FY22:
    • Revenue from operation: Rs 4,236.12 million vs Rs 4,336.47 million, down 2.31% YoY
    • EBITDA (Excl. Other Income): Rs 605.81 million vs Rs 1,082.35 million, down 44.03% YoY
    • EBITDA margin: 14.30% vs 24.96%
    • Profit before tax: Rs 447.79 million vs Rs 1,041.21 million, down 56.99% YoY
    • Profit after tax: Rs 454.87 million vs Rs 958.74 million, down 52.56% YoY
    • PAT margin: 10.74% vs 22.11%

Commenting on the results, Chintan Shah, Managing Director, said, “Over the past decade, the Indian chemical sector had been growing rapidly. However, FY23 had been a roller coaster year for most of the chemical industries. Despite all geopolitical uncertainties, the Indian chemical industry showed good resilience. Many of the challenges are set to persist in 2023. Against a backdrop of fear of global recession and expectation of muted demand till H1FY24, Tatva Chintan continues to remain fairly optimistic about achieving reasonable growth. Most of the key raw material prices have dropped by 15%-25% which is also translating into reduced prices of the finished products. So, this becomes a big challenge for us to achieve revenue growth. Also due to muted global demand across most of the sectors, we are seeing continuous cost pressures coming from customers which would translate into slightly lower spreads on margins. I feel Tatva Chintan is fortunate with the timing of the launch of new products on a commercial scale during this financial year and also with the gradual rebound in the SDAs demand. Despite the challenging year ahead and even with the reduced product pricing we anticipate to grow by 20%-30% in FY24. Also, we anticipate slightly improving the EBITDA margins due to forecasted change in the product mix.”

 

 

 

Result PDF

Specialty chemicals firm Tatva Chintan Pharma Chem announced Q3FY23 results:

  • Consolidated Q3FY23 vs Q3FY22:
    • Revenue from Operations for the quarter was Rs 1,206 million, increased by 15%
    • EBITDA for the quarter was Rs 179 million, declined by 25%
    • EBIDTA Margin for the quarter was at 15%
    • Net Profit for the quarter was Rs 116 million, declined by 49%
    • Net Profit Margin for the quarter was at 10%
    • Basic and Diluted EPS for the quarter was Rs 5.24 per share
  • 9MFY23 vs 9MFY22:
    • Revenue from Operations for the nine months was Rs 2,991 million, declined by 11%
    • EBITDA for the nine months was Rs 443 million, declined by 49%
    • EBIDTA Margin for the nine months was at 15%
    • Net Profit for the nine months was Rs 285 million, declined by 64%
    • Net Profit Margin for the nine months was at 10%
    • Basic and Diluted EPS for the nine months was Rs 12.87 per share

Commenting on the results, Mr. Chintan Shah, Managing Director said during this quarter, the company reported revenue of Rs 1,206 million, a growth of 15% YoY and 34% QoQ respectively. As anticipated, improved offtake in SDA segment is reflected in numbers of this quarter. EBITDA during this quarter was Rs 179 million, a decline of 25% YoY and a growth of 60% QoQ respectively. Net Profit was Rs 116 million, a decline of 49% YoY and a growth of 63% QoQ basis. During the quarter, prices of basic chemicals and commodities continue to remain very high. We have witnessed rampant currency fluctuations across various geographies this quarter, particularly adverse movements in Euro and Yen. Keeping in mind our long-term partnerships and associations with select key customers belonging to these geographies, we marginally reduced the prices and, in few cases, opted not to ask for price increase and absorbed certain increased costs ourselves. During the quarter, the inventory at consolidated levels have come down from Rs 2,030 to Rs 1,762 million.

During this quarter, there is a marginal decline in power/fuel costs, and significant drop in shipping cost since mid-November. The solvent prices have started to rationalize since Q3FY23.

By demonstrating our capabilities to run specialized chemistries, we are seeing a consistent rise in the confidence and comfort of large customers. There have been developments in R&D, plant scale trials in various product categories during the quarter.

The key watch areas would remain how the European energy crisis roll out over the next few months and how the demand revival for heavy duty commercial vehicles pans out. Also, with the China economy opening up, it would be important to observe how quickly their business rebounds.

We are happy to inform that the capex at our Dahej SEZ plant is completed and trial runs are underway. Please note that nearly 93% of the IPO funds have been utilized so far. The expansion of R&D facility at Vadodara is on finishing stage.

Result PDF

Tatva Chintan Pharma Chem announced Q2FY23 results:

  • Consolidated:
    • YoY Q2FY23 vs Q2FY22:
      • Revenue from Operations for the quarter was Rs. 901 million, which declined by 27%
      • EBITDA for the quarter was Rs. 112 million, which declined by 68%
      • EBIDTA Margin for the quarter was at 12%
      • Net Profit for the quarter was Rs. 71 million, which declined by 78%
      • Net Profit Margin for the quarter was at 8%
      • Basic and Diluted EPS for the quarter was Rs. 3.21 per share
    • YoY  H1FY23 vs H1FY22:
      • Revenue from Operations for the half year was Rs. 1,785 million, which declined by 23%
      • EBITDA for the half year was Rs. 264 million, which declined by 57%
      • EBIDTA Margin for the half year was at 15%
      • Net Profit for the half year was Rs. 169 million, which declined by 70%
      • Net Profit Margin for the half year was at 9%
      • Basic and Diluted EPS for the half year was Rs. 7.63 per share

Commenting on Q2FY23 Results, Mr. Chintan Shah, Managing Director, said, EBITDA during this quarter was Rs. 112 million, a decline of 68% YoY and 27% QoQ. EBIDTA includes a forex loss of Rs. 31.85 million, so the actual operational EBIDTA during the quarter is Rs. 143.62 million which translates into an EBIDTA margin of 16%. Forex loss is mainly because of the MTM of the forward contract due to the depreciating rupee.

PAT was Rs. 71 million, a decline of 78% YoY and 27% QoQ. Compared to the QoQ basis, the profitability has dropped due to an increase in costs such as power & fuel, packing and employee costs during this quarter

Result PDF

Trending News

US-Iran Peace Deal to Reopen Hormuz: Global Shipping Eases & Crude Oil Prices Plunge 4%

According to media sources, US and Iran have reached a peace deal which includes immediate reopening of Strait of Hormuz. 

Published on 15-Jun-2026 09:13

Dr Reddy’s, MSN launch first generic Bosutinib tablets in US with 180-day exclusivity

Dr. Reddy’s Lab has announced the first-to-market launch of Bosutinib Tablets in US. Dr. Reddy’s has collaborated with MSN Laboratories on this product. 

Published on 15-Jun-2026 09:12

POWERGRID Wins Bid to Build Kakinada Green Hydrogen Transmission Network in Andhra Pradesh

Power Grid Corporation of India (POWERGRID) has been declared the successful bidder under the Tariff Based Competitive Bidding (TBCB) route for the project "Transmission System for proposed Green Hydrogen/Green Ammonia projects in Kakinada area (Phase-I)" on a Build, Own, Operate and Transfer (BOOT) basis. 

Published on 15-Jun-2026 09:11

Radico Khaitan Unveils Premium Avatar for After Dark Blue Whisky to Elevate Deluxe Segment!

Radico Khaitan has announced the launch of all-new premium avatar of After Dark Blue Grain Whisky. 

Published on 15-Jun-2026 09:10

KIMS Board Approves ₹600Cr Preferential Warrant Issue to Promoters; EGM Set for July 9

The board of Krishna Institute of Medical Sciences Limited (KIMS) has approved a preferential issue of 77.02 lakh warrants to promoter and promoter-group entities, raising nearly ₹600 crore. 

Published on 15-Jun-2026 09:09

LG India outlines 'Zero Labor Home' strategy with AI appliances and robots to lead market growth

As per exchange fillings, LG Electronics India outlined its long-term AI Home strategy, centered on AI-powered appliances, ThinQ AI orchestration and autonomous home robots, targeting a ‘Zero Labor Home’ ecosystem. 

Published on 15-Jun-2026 09:08

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Get it on google Play Store Download on the App Store
market app